Patents by Inventor Nicholas Alan ZIA

Nicholas Alan ZIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiopharmaceuticals, radioimaging agents, and uses thereof
    Patent number: 11970503
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: April 30, 2024
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly
  • Targeting compounds and methods for their production
    Patent number: 11951189
    Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: April 9, 2024
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Paul Stephen Donnelly, Nicholas Alan Zia
  • RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF
    Publication number: 20230382918
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: August 11, 2023
    Publication date: November 30, 2023
    Applicant: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY
  • FORMULATIONS OF PSMA IMAGING AGENTS
    Publication number: 20220313600
    Abstract: The present invention relates to formulations of radiolabeled compounds that are of use in radiotherapy and diagnostic imaging related to prostate specific membrane antigen (PSMA).
    Type: Application
    Filed: May 22, 2020
    Publication date: October 6, 2022
    Applicant: Clarity Pharmaceuticals Limited
    Inventors: Paul Stephen DONNELLY, Nicholas Alan ZIA, Lawson Kyle SPARE, Ellen Marianne VAN DAM, Kevin Kar Weng KUAN
  • RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF
    Publication number: 20220315596
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: June 7, 2022
    Publication date: October 6, 2022
    Applicant: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY
  • Radiopharmaceuticals, radioimaging agents, and uses thereof
    Patent number: 11384088
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: July 12, 2022
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly
  • RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF
    Publication number: 20220041608
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: March 10, 2021
    Publication date: February 10, 2022
    Applicant: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY
  • Radiopharmaceuticals, radioimaging agents, and uses thereof
    Patent number: 10975089
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 13, 2021
    Assignee: Clarity Pharmaceuticals Ltd
    Inventors: Nicholas Alan Zia, Paul Stephen Donnelly
  • TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTION
    Publication number: 20210030900
    Abstract: The present invention is directed to sarcophagine based compounds of formula (I). The compounds can complex a radioisotope, such as 64-copper and hence are useful in radioimaging and radiotherapy of cancers, e.g. colorectal cancer. The compounds work via a pre-targeting imaging approach in which the tetrazine reacts via click chemistry with a functional group such as a transcyclooctene which is pre-bound to a ligand such as a tumour specific antibody.
    Type: Application
    Filed: April 11, 2019
    Publication date: February 4, 2021
    Inventors: Paul Stephen Donnelly, Nicholas Alan Zia
  • RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF
    Publication number: 20200095257
    Abstract: The present invention relates to compounds that are useful as radiopharmaceuticals and radioimaging agents which bear a radionuclide-chelating agent. These coordinated compounds are useful in radiotherapy and diagnostic imaging. The invention also relates to methods of diagnosis, prognosis and therapy utilising the non-coordinated and radiolabelled compounds of the invention.
    Type: Application
    Filed: June 5, 2018
    Publication date: March 26, 2020
    Applicant: THE UNIVERSITY OF MELBOURNE
    Inventors: Nicholas Alan ZIA, Paul Stephen DONNELLY